B Lukacs|M Naidicht - JoVE Visualize

Showing results (1-10 of 61) with videos related to

Pageof 7

Sort By:

Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|June 1, 1994

[The Medical Information System Program in urology: what should be considered?]B Lukacs, M Naidicht

European Urology|January 1, 1997

Using a large clinical database to assess the effectiveness of alfuzosinB Lukacs

Presse Medicale (Paris, France : 1983)|October 28, 1995

[Why and how to measure the quality of life? Questions to be asked by the urologist]B Lukacs

Prostate Cancer and Prostatic Diseases|December 24, 2002

Assessment of male sexual functionB Lukacs

European Urology|November 24, 1999

Management of symptomatic BPH in France: who is treated and how?B Lukacs

Urology|March 29, 2000

One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General PracticeB Lukacs, J C Grange, D Comet

European Urology|January 1, 1993

Long-term quality of life in patients with benign prostatic hypertrophy: preliminary results of a cohort survey of 7,093 patients treated with an alpha-1-adrenergic blocker, alfuzosin. QOL BPH Study Group in General PracticeB Lukacs, C McCarthy, J C Grange

Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|April 10, 2019

Voiding urethrocystoscopy: A new concept for benign prostatic obstruction characterizationB Lukacs, S Doizi, J-N Cornu

Urology|November 1, 1996

Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year resultsB Lukacs, A Leplège, P Thibault, et al.

Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 1, 1994

[Development and validation of a quality of life scale associated with health status, specific for benign hypertrophy of the prostate and including a sexuality evaluation scale]B Lukacs, C McCarthy, A Leplege, et al.

Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:

Pageof 7

Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|June 1, 1994

[The Medical Information System Program in urology: what should be considered?]B Lukacs, M Naidicht

European Urology|January 1, 1997

Using a large clinical database to assess the effectiveness of alfuzosinB Lukacs

Presse Medicale (Paris, France : 1983)|October 28, 1995

[Why and how to measure the quality of life? Questions to be asked by the urologist]B Lukacs

Prostate Cancer and Prostatic Diseases|December 24, 2002

Assessment of male sexual functionB Lukacs

European Urology|November 24, 1999

Management of symptomatic BPH in France: who is treated and how?B Lukacs

Urology|March 29, 2000

One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General PracticeB Lukacs, J C Grange, D Comet

European Urology|January 1, 1993

Long-term quality of life in patients with benign prostatic hypertrophy: preliminary results of a cohort survey of 7,093 patients treated with an alpha-1-adrenergic blocker, alfuzosin. QOL BPH Study Group in General PracticeB Lukacs, C McCarthy, J C Grange

Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|April 10, 2019

Voiding urethrocystoscopy: A new concept for benign prostatic obstruction characterizationB Lukacs, S Doizi, J-N Cornu

Urology|November 1, 1996

Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year resultsB Lukacs, A Leplège, P Thibault, et al.

Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 1, 1994

[Development and validation of a quality of life scale associated with health status, specific for benign hypertrophy of the prostate and including a sexuality evaluation scale]B Lukacs, C McCarthy, A Leplege, et al.

Pageof 7